| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Megalin is a multiligand endocytotic receptor involving in the reabsorption of calcitriol and vitamin D binding protein in renal proximal tubules. Parathyroid glands also express megalin, however, little is known about its expressions and pathophysiological roles in hyperfunctioning parathyroid tumors. Its expression was observed in plasma membranes and cytoplasm in normal parathyroid glands. The expressions decreased in tumors with primary hyperparathyroidism and secondary hyperparathyroidism of uremia (SHPT) compared with strong expression in normal parathyroid glands. In SHPT, its expression was often particularly depressed in nodular areas, compared with adjacent diffuse hyperplasias. The reduced expression of both megalin and VDR may enhance vitamin D resistance and hyper-secretion of PTH from these tumors.
|
